On May 12, 2025 Cellectis reported financial results for the first quarter 2025, ending March 31, 2025, and provided a business update (Press release, Cellectis, MAY 12, 2025, View Source [SID1234653902]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

We are making progress in our wholly-owned clinical studies and in the three programs under our strategic partnership with AstraZeneca. We will continue to focus our efforts and resources on advancing these core programs and are looking forward to the results expected over the next few months » said André Choulika, Ph.D., Chief Executive Officer at Cellectis.

On the May 12, 2025 British techbio innovator Etcembly, reported that it has signed a collaboration agreement with DJS Antibodies, a part of AbbVie, to accelerate the discovery of novel antibody therapeutics (Press release, Etcembly, MAY 12, 2025, View Source [SID1234652900]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Etcembly’s flagship AI platform, EMLy, stands as the most advanced immune discovery and engineering technology. Bringing together billions of T-cell receptor (TCR) and antibody sequences with cutting-edge bioinformatics, large language models (LLMs) and structural modeling, EMLy enables the exploration of immune system interactions with targets in unprecedented detail.

This inaugural partnership will leverage EMLy’s deep immune repertoire analysis to identify novel antibodies against an undisclosed G protein-coupled receptor (GPCR) target in autoimmune disease.

Michelle Teng, CEO of Etcembly said, "We’ve already showcased EMLy’s ability to discover and optimize picomolar affinity TCRs in months rather than years. With our expanded capabilities now encompassing antibody discovery and engineering, we are thrilled to partner with DJS Antibodies to address challenging targets and drive faster, smarter development of next-generation biotherapeutics.

On May 12, 2025 Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, reported that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at three upcoming investor conferences (Press release, Nuvation Bio, MAY 12, 2025, View Source [SID1234652899]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 3:00 p.m. ET in New York, NY
2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 p.m. ET in New York, NY
TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO (Free ASCO Whitepaper) & EHA (Free EHA Whitepaper) on Wednesday, May 28, 2025, at 3:30 p.m. ET (virtual)
Live webcasts of each presentation will be available on the Nuvation Bio website at View Source An archived recording will be available for 90 days following each event.

On May 12, 2025 Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, reported that management will participate in the following investor conferences (Press release, Tyra Biosciences, MAY 12, 2025, View Source [SID1234652898]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bank of America Global Healthcare Conference, May 13-15, 2025
Format: Fireside chat and one-on-one investor meetings
Presentation Date/Time: Tuesday, May 13, 2025, at 5:15 PM PT
Location: Las Vegas, NV

Jefferies Global Healthcare Conference, June 3-5, 2025
Format: One-on-one investor meetings
Location: New York, NY

UBS Biotech 1×1 Symposium, June 24, 2025
Format: One-on-one investor meetings
Location: New York, NY

A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website.

On May 12, 2025 Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies reported that three research programs, in collaboration with Vitalgen BioPharma Co., Ltd. ("Vitalgen"), will be showcased in one oral presentation and two poster sessions at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 28th annual meeting in New Orleans, LA from May 13th to 17th (Press release, Grit Bio, MAY 12, 2025, View Source [SID1234652897]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Grit Bio will provide the updates of three preclinical programs, including APC-targeted neoantigen cancer vaccine, non-viral-nanoparticle-directed in vivo CAR-T, and LNP-mediated gene editing in tumor infiltrating lymphocyte (TIL). The details of three presentations are:

Title: APC-Targeted LNP Enables Systemic Delivery of Neoantigen mRNA Vaccines and Enhanced Antigen-Specific T Cell Responses
Presentation Type: Oral
Time: 5:15-5:30 pm local time, Thursday, May 15th
Speaker: Pin Wang, Ph.D., CSO of Grit Biotechnology
Title: In Vivo CAR-T Therapy Powered by Novel CLAMP Technology for T cell-Targeted mRNA Delivery
Presentation Type: Poster
Time: 5:30-7:00 pm local time, Wednesday, May 14th
Poster #: 1282
Title: Enhancing Production and Functional Potential of Tumor-Infiltrating Lymphocytes via Lipid Nanoparticle-Mediated CRISPR/Cas9 Gene Editing
Presentation Type: Poster
Time: 5:30-7:00 pm local time, Thursday, May 15th
Poster #: 1776
"Through a strategic collaboration with Vitalgen, we are pioneering next-generation immunotherapies and precision delivery technologies. This synergy accelerates the development of advanced therapies with transformative improvements in safety and efficacy. We are now expanding those innovations toward global clinical implementation." said Dr. Yarong Liu, founder and Chief Executive Officer of Grit Biotechnology.